Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

I-Mab stock price, quote, forecast and news

IMAB
US44975P1030
A2PVC6

Price

9.78
Today +/-
+0
Today %
+0 %
P

I-Mab Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into I-Mab, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by I-Mab from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects I-Mab’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of I-Mab. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into I-Mab’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing I-Mab’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on I-Mab’s growth potential.

I-Mab Revenue, EBIT and net profit per share

DateI-Mab RevenueI-Mab EBITI-Mab Net Income
2029e391.71 M undefined0 undefined605.08 M undefined
2028e76.71 M undefined-1.34 B undefined-756.35 M undefined
2027e7.4 M undefined-1.33 B undefined-1.6 B undefined
2026e1.02 M undefined-203.52 M undefined-195.94 M undefined
2025e765,000 undefined-191.72 M undefined-429.95 M undefined
2024e765,000 undefined-180.9 M undefined-458.28 M undefined
202327.64 M undefined-1.24 B undefined-1.47 B undefined
2022-221.6 M undefined-1.97 B undefined-2.51 B undefined
202188 M undefined-2.07 B undefined-2.33 B undefined
20201.54 B undefined155.6 M undefined470.9 M undefined
201930 M undefined-1.47 B undefined-1.49 B undefined
201853.8 M undefined-438.6 M undefined-402.8 M undefined
201711.6 M undefined-281 M undefined-298.2 M undefined

I-Mab Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
0.010.050.031.540.09-0.220.030000.010.080.39
-381.82-43.405,040.00-94.29-351.14-112.22---600.00985.71414.47
----46.59112.22100.00------
000041-24827000000
-281-438-1,465155-2,071-1,969-1,236-180-191-203-1,326-1,3400
-2,554.55-826.42-4,883.3310.05-2,353.41890.95-4,577.78---20,300.00-18,942.86-1,763.16-
-298-402-1,485470-2,331-2,507-1,465-458-429-195-1,595-756605
-34.90269.40-131.65-595.967.55-41.56-68.74-6.33-54.55717.95-52.60-180.03
131.2131.2131.2157.2174.7189.8203.9000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The I-Mab Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the I-Mab is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of I-Mab provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand I-Mab's financial health and stability.

Assets

I-Mab's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that I-Mab must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of I-Mab after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into I-Mab's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
-298-402-1,452470-2,331-2,507
169141426
0000014
25147184-240394552
0.03-0.030.760.681.561.17
143100
000000
-252-280-868433-973-1,102
-20-14-12-8-29-45
-1579212-201-727458
-13723224-193-697504
000000
21040-30-50019
0.391.440.180.70.730.02
0.761.480.153.440.590.04
0.16002.79-0.140
000000
0.351.27-0.493.57-1.24-0.21
-272.5-295.1-880.2425.6-1,003-1,148.6
000000

I-Mab stock margins

The I-Mab margin analysis displays the gross margin, EBIT margin, as well as the profit margin of I-Mab. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for I-Mab.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the I-Mab's sales revenue. A higher gross margin percentage indicates that the I-Mab retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the I-Mab's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the I-Mab's total revenue generated. When comparing the revenue margin year over year, investors can gauge the I-Mab's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the I-Mab. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the I-Mab's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

I-Mab Margin History

I-Mab Gross marginI-Mab Profit marginI-Mab EBIT marginI-Mab Profit margin
2029e100 %0 %154.47 %
2028e100 %-1,747.07 %-986.03 %
2027e100 %-17,928.96 %-21,559.61 %
2026e100 %-19,952.57 %-19,209.46 %
2025e100 %-25,062.02 %-56,202.64 %
2024e100 %-23,647.2 %-59,905.38 %
2023100 %-4,471.2 %-5,302.03 %
2022112.27 %888.76 %1,131.45 %
202147.27 %-2,353.75 %-2,649.43 %
2020100 %10.09 %30.52 %
2019100 %-4,883.33 %-4,950 %
2018100 %-815.24 %-748.7 %
2017100 %-2,422.41 %-2,570.69 %

I-Mab Stock Sales Revenue, EBIT, Earnings per Share

The I-Mab earnings per share therefore indicates how much revenue I-Mab has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue I-Mab earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates I-Mab's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of I-Mab’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating I-Mab's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

I-Mab Revenue, EBIT and net profit per share

DateI-Mab Sales per ShareI-Mab EBIT per shareI-Mab Earnings per Share
2029e2.11 undefined0 undefined3.25 undefined
2028e0.41 undefined0 undefined-4.07 undefined
2027e0.04 undefined0 undefined-8.57 undefined
2026e0.01 undefined0 undefined-1.05 undefined
2025e0 undefined0 undefined-2.31 undefined
2024e0 undefined0 undefined-2.46 undefined
20230.14 undefined-6.06 undefined-7.19 undefined
2022-1.17 undefined-10.38 undefined-13.21 undefined
20210.5 undefined-11.86 undefined-13.35 undefined
20209.81 undefined0.99 undefined3 undefined
20190.23 undefined-11.17 undefined-11.32 undefined
20180.41 undefined-3.34 undefined-3.07 undefined
20170.09 undefined-2.14 undefined-2.27 undefined

I-Mab business model

I-Mab is a Chinese biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer and autoimmune diseases. It was founded in 2016 by Dr. Jingwu Zang and is based in Shanghai, China. I-Mab's business model focuses on the development of antibody therapies tailored to the needs of cancer and autoimmune patients. They utilize the latest research and development to create therapies that address the unmet market demand. They work on cancer immunotherapy, including CAR-T cell therapy, and also on immunotherapy for autoimmune diseases, including rare ones. Their goal is to improve the lives of patients with cancer and autoimmune diseases through innovative biotechnology and research. They have promising products in development and clinical trials, such as AMG 228 and TJM2. They aim to make a significant contribution to healthcare with their dedicated team of researchers and scientists. I-Mab is one of the most popular companies on Eulerpool.com.

I-Mab SWOT Analysis

Strengths

1. Strong portfolio of innovative and potential breakthrough therapies in the biopharmaceutical industry.

2. Strategic partnerships and collaborative agreements with leading global pharmaceutical companies, enhancing research and development capabilities.

3. Established presence and reputation in the Chinese pharmaceutical market, a rapidly growing segment.

Weaknesses

1. Relatively small scale compared to larger pharmaceutical companies, limiting resources and competitive advantage.

2. High dependence on successful clinical trials and regulatory approvals, which pose significant risks to product development.

3. Limited global footprint beyond Chinese market, potentially impacting market reach and market penetration.

Opportunities

1. Growing global demand for innovative therapies presents opportunities for I-Mab to expand its market share outside of China.

2. Increasing government support and favorable policies in China encourage domestic biopharmaceutical companies like I-Mab to further invest in research and development.

3. Collaborative partnerships with academic institutions and research centers can provide access to additional expertise, resources, and potential breakthroughs.

Threats

1. Intense competition from both domestic and international pharmaceutical companies in the biopharmaceutical market.

2. Regulatory uncertainties and stringent approval processes in different markets may delay or hinder product commercialization.

3. Potential challenges in intellectual property protection and patent disputes may affect the company's ability to maximize the value of its innovations.

I-Mab historical P/E ratio, EBIT, and P/S ratio.

I-Mab shares outstanding

The number of shares was I-Mab in 2023 — This indicates how many shares 203.904 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue I-Mab earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates I-Mab's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of I-Mab’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating I-Mab's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for I-Mab.

Eulerpool ESG Scorecard© for the I-Mab stock

Eulerpool World ESG Rating (EESG©)

36/ 100

🌱 Environment

21

👫 Social

55

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees66.67
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

I-Mab list of shareholders

%
Name
Stocks
Change
Date
5.46 % CBC Group10,160,7709,787,21312/31/2022
3.71 % HHLR Advisors, Ltd.6,909,220012/31/2023
2.84 % GIC Private Limited5,274,436564,65312/31/2022
0.62 % Two Sigma Investments, LP1,144,674268,44812/31/2023
0.30 % Temasek Holdings Pte. Ltd.566,650012/31/2023
0.29 % Zang (Jingwu Zhang)545,709198,18512/31/2023
0.29 % GSA Capital Partners LLP538,119342,57312/31/2023
0.23 % Morgan Stanley & Co. LLC425,988-471,06812/31/2023
0.17 % Abaris Investment Management AG315,000124,00010/31/2023
0.17 % CPP Investment Board313,600267,55812/31/2023
1
2
3
4
5
...
10

Most common questions regarding I-Mab

What values and corporate philosophy does I-Mab represent?

I-Mab is a biopharmaceutical company that is dedicated to discovering and developing innovative biologics to address unmet medical needs. Their corporate philosophy revolves around a patient-centric approach, focusing on improving patients' lives through advanced therapies. I-Mab values integrity, collaboration, and scientific excellence, aiming to provide breakthrough treatments for diseases with high unmet medical needs. With a strong commitment to delivering novel solutions, I-Mab continuously strives to be at the forefront of research and development in the biopharmaceutical industry.

In which countries and regions is I-Mab primarily present?

I-Mab is primarily present in China and the United States.

What significant milestones has the company I-Mab achieved?

I-Mab, a leading biopharmaceutical company, has achieved significant milestones throughout its journey. The company successfully conducted a Phase 3 clinical trial for its innovative therapy in treating diffuse large B-cell lymphoma, demonstrating its commitment to advancing healthcare solutions. Additionally, I-Mab received the U.S. FDA Fast Track Designation for its potential treatment of multiple myeloma, recognizing the company's dedication to developing breakthrough therapies. Furthermore, I-Mab forged strategic partnerships with renowned global pharmaceutical companies, reinforcing its position in the global market. Overall, I-Mab's achievements highlight its exceptional growth and commitment towards improving patients' lives through groundbreaking treatments.

What is the history and background of the company I-Mab?

I-Mab is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and autoimmune diseases. Founded in 2016, I-Mab focuses on the discovery and development of antibody-based drugs by leveraging its proprietary discovery and development platforms. This Chinese company has a strong emphasis on research and development, working on a diverse pipeline of potential drugs targeting various diseases. With a commitment to delivering novel and effective solutions, I-Mab has garnered recognition within the pharmaceutical industry for its innovative approach and dedication to improving patients' lives.

Who are the main competitors of I-Mab in the market?

The main competitors of I-Mab in the market include large biopharmaceutical companies such as Junshi Biosciences, Legend Biotech, BeiGene, and Innovent Biologics.

In which industries is I-Mab primarily active?

I-Mab is primarily active in the pharmaceutical industry.

What is the business model of I-Mab?

I-Mab is a clinical-stage biopharmaceutical company based in China. Its business model revolves around the discovery, development, and commercialization of innovative and differentiated biologics. I-Mab focuses on developing novel antibodies to address unmet medical needs in the fields of oncology, immuno-oncology, and autoimmune diseases. With a strong pipeline of potential therapies, I-Mab aims to bring groundbreaking treatments to patients globally. By advancing its drug candidates through rigorous research and strategic partnerships, I-Mab aims to revolutionize healthcare and improve patient outcomes.

What is the P/E ratio of I-Mab 2024?

The I-Mab P/E ratio is -4.35.

What is the P/S ratio of I-Mab 2024?

The I-Mab P/S ratio is 2,605.55.

What is the AlleAktien quality score of I-Mab?

The AlleAktien quality score for I-Mab is 1/10.

What is the revenue of I-Mab 2024?

The expected I-Mab revenue is 765,000 CNY.

How high is the profit of I-Mab 2024?

The expected I-Mab profit is -458.28 M CNY.

What is the business model of I-Mab

I-Mab is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious diseases like cancer and immune disorders. They have a strong pipeline of products in the fields of oncology, autoimmune diseases, and cardiovascular diseases. They have partnerships with other companies to market their products worldwide. Overall, their business model is centered around developing and marketing effective therapies for challenging diseases and they have a unique partnership strategy.

What is the I-Mab dividend?

I-Mab pays a dividend of 0 CNY distributed over payouts per year.

How often does I-Mab pay dividends?

The dividend cannot currently be calculated for I-Mab or the company does not pay out a dividend.

What is the I-Mab ISIN?

The ISIN of I-Mab is US44975P1030.

What is the I-Mab WKN?

The WKN of I-Mab is A2PVC6.

What is the I-Mab ticker?

The ticker of I-Mab is IMAB.

How much dividend does I-Mab pay?

Over the past 12 months, I-Mab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, I-Mab is expected to pay a dividend of 0 CNY.

What is the dividend yield of I-Mab?

The current dividend yield of I-Mab is .

When does I-Mab pay dividends?

I-Mab pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of I-Mab?

I-Mab paid dividends every year for the past 0 years.

What is the dividend of I-Mab?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is I-Mab located?

I-Mab is assigned to the 'Health' sector.

Wann musste ich die Aktien von I-Mab kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of I-Mab from 7/31/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did I-Mab pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of I-Mab in the year 2023?

In the year 2023, I-Mab distributed 0 CNY as dividends.

In which currency does I-Mab pay out the dividend?

The dividends of I-Mab are distributed in CNY.

All fundamentals about I-Mab

Our stock analysis for I-Mab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of I-Mab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.